Skip to main content
. Author manuscript; available in PMC: 2018 May 1.
Published in final edited form as: Cancer. 2017 Mar 3;125(5):332–340. doi: 10.1002/cncy.21841

Table 1. CEC positivity by diagnosis.

All 171 91 (53.2%) 24 (14.0%) 56 (32.7%)
PDAC 108 53 (49.1%) 19 (17.6%) 36 (33.3%)
Cholangiocarcinoma 8 4 (50.0%) 0 (0%) 4 (50.0%)
Ampullary CA 7 4 (57.1%) 0 (0%) 3 (42.9%)
NET 9 6 (66.7%) 2 (22.2%) 1 (11.1%)
SPN 3 2 (66.7%) 0 (0%) 1 (33.3%)
Acinar cell CA 1 0 (0%) 0 (0%) 1 (100.0%)
IPMN 16 12 (75.0%) 0 (0%) 4 (25.0%)
MCN 1 1 (100.0%) 0 (0%) 0 (0%)
Ampullary adenoma 3 1 (33.3%) 0 (0%) 2 (66.7%)
Serous cystadenoma 2 2 (100.0%) 0 (0%) 0 (0%)
Splenic epidermoid cyst 1 0 (0%) 0 (0%) 1 (100.0%)
Pancreatitis 12 6 (50.0%) 3 (25.0%) 3 (25.0%)

CEC: Circulating epithelioid cells. +: Positive. Susp: suspicious. -: Negative. PDAC: Pancreatic ductal adenocarcinoma. CA: Carcinoma. NET: Neuroendocrine tumor. SPN: Solid-pseudopapillary neoplasm. IPMN: Intraductal papillary mucinous neoplasm. MCN: Mucinous cystic neoplasm. SCA: Serous cystadenoma